Literature DB >> 20143418

Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma.

Blanca Espinet1, Itziar Salaverria, Sílvia Beà, Neus Ruiz-Xivillé, Olga Balagué, Marta Salido, Dolors Costa, Joaquim Carreras, Ana Eugenia Rodríguez-Vicente, Juan Luís García, Jesús María Hernández-Rivas, María José Calasanz, Reiner Siebert, Ana Ferrer, Antonio Salar, Ana Carrió, Natividad Polo, José Antonio García-Marco, Alicia Domingo, Eva González-Barca, Vicenç Romagosa, Isabel Marugán, Armando López-Guillermo, Fuensanta Millá, José Luís Mate, Elisa Luño, Carmen Sanzo, Rosa Collado, Isabel Oliver, Sebastià Monzó, Antonio Palacín, Teresa González, Francesc Sant, Ramon Salinas, María Teresa Ardanaz, Llorenç Font, Lourdes Escoda, Lourdes Florensa, Sergi Serrano, Elias Campo, Francesc Solé.   

Abstract

Mantle cell lymphoma (MCL) is a mature B-cell neoplasm with an aggressive behavior, characterized by the t(11;14)(q13;q32). Several secondary genetic abnormalities with a potential role in the oncogenic process have been described. Studies of large MCL series using conventional cytogenetics, and correlating with proliferation and survival, are scarce. We selected 145 MCL cases at diagnosis, displaying an aberrant karyotype, from centers belonging to the Spanish Cooperative Group for Hematological Cytogenetics. Histological subtype, proliferative index and survival data were ascertained. Combined cytogenetic and molecular analyses detected CCND1 translocations in all cases, mostly t(11;14)(q13;q32). Secondary aberrations were present in 58% of patients, the most frequent being deletions of 1p, 13q and 17p, 10p alterations and 3q gains. The most recurrent breakpoints were identified at 1p31-32, 1p21-22, 17p13, and 1p36. Aggressive blastoid/pleomorphic variants displayed a higher karyotypic complexity, a higher frequency of 1p and 17p deletions and 10p alterations, a higher proliferation index and poor survival. Gains of 3q and 13q and 17p13 losses were associated with reduced survival times. Interestingly, gains of 3q and 17p losses added prognostic significance to the morphology in a multivariate analysis. Our findings confirm previous observations indicating that proliferation index, morphology and several secondary genetic alterations (3q gains and 13q and 17p losses) have prognostic value in patients with MCL. Additionally, we observed that 3q gains and 17p losses detected by conventional cytogenetics are proliferation-independent prognostic markers indicating poor outcome. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20143418     DOI: 10.1002/gcc.20754

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  22 in total

1.  Mantle cell lymphoma harboring Burkitt's-like translocations presents differential expression of aurora kinase genes compared with others 8q abnormalities.

Authors:  Fábio Morato de Oliveira; Ana Paula Nunes Rodrigues-Alves; Antônio Roberto Lucena-Araújo; Ferdinando de Paula Silva; Fernanda Borges da Silva; Roberto Passetto Falcão
Journal:  Med Oncol       Date:  2014-03-29       Impact factor: 3.064

2.  Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing.

Authors:  Prasath Pararajalingam; Krysta M Coyle; Sarah E Arthur; Nicole Thomas; Miguel Alcaide; Barbara Meissner; Merrill Boyle; Quratulain Qureshi; Bruno M Grande; Christopher Rushton; Graham W Slack; Andrew J Mungall; Constantine S Tam; Rishu Agarwal; Sarah-Jane Dawson; Georg Lenz; Sriram Balasubramanian; Randy D Gascoyne; Christian Steidl; Joseph Connors; Diego Villa; Timothy E Audas; Marco A Marra; Nathalie A Johnson; David W Scott; Ryan D Morin
Journal:  Blood       Date:  2020-07-30       Impact factor: 22.113

Review 3.  Mantle cell lymphoma--a spectrum from indolent to aggressive disease.

Authors:  Birgitta Sander; Leticia Quintanilla-Martinez; German Ott; Luc Xerri; Isinsu Kuzu; John K C Chan; Steven H Swerdlow; Elias Campo
Journal:  Virchows Arch       Date:  2015-08-23       Impact factor: 4.064

4.  TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage.

Authors:  Hua-Jie Dong; Li-Tao Zhou; Cheng Fang; Lei Fan; Dan-Xia Zhu; Yin-Hua Wang; Jian-Yong Li; Wei Xu
Journal:  Med Oncol       Date:  2011-11-06       Impact factor: 3.064

5.  Leukemic non-nodal mantle cell lymphomas have a distinct phenotype and are associated with deletion of PARP1 and 13q14.

Authors:  Mathieu Gallo; Valère Cacheux; Laure Vincent; Caroline Bret; Ariane Tempier; Caroline Guittard; Alexandra Macé; Nicolas Leventoux; Valérie Costes; Vanessa Szablewski
Journal:  Virchows Arch       Date:  2016-09-07       Impact factor: 4.064

6.  Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.

Authors:  I Brian Greenwell; Ashley D Staton; Michael J Lee; Jeffrey M Switchenko; Debra F Saxe; Joseph J Maly; Kristie A Blum; Natalie S Grover; Stephanie P Mathews; Max J Gordon; Alexey V Danilov; Narendranath Epperla; Timothy S Fenske; Mehdi Hamadani; Steven I Park; Christopher R Flowers; Jonathon B Cohen
Journal:  Cancer       Date:  2018-03-26       Impact factor: 6.860

Review 7.  Iodothyronine deiodinases and cancer.

Authors:  A Piekiełko-Witkowska; A Nauman
Journal:  J Endocrinol Invest       Date:  2011-05-27       Impact factor: 4.256

Review 8.  Risk factors for etiology and prognosis of mantle cell lymphoma.

Authors:  Yu Wang; Shuangge Ma
Journal:  Expert Rev Hematol       Date:  2014-02-22       Impact factor: 2.929

9.  A rare case of t(11;22) in a mantle cell lymphoma like B-cell neoplasia resulting in a fusion of IGL and CCND1: case report.

Authors:  Cristiano Krings Rocha; Inka Praulich; Iris Gehrke; Michael Hallek; Karl-Anton Kreuzer
Journal:  Mol Cytogenet       Date:  2011-04-01       Impact factor: 2.009

10.  Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.

Authors:  Preetesh Jain; Shaojun Zhang; Rashmi Kanagal-Shamanna; Chi Young Ok; Krystle Nomie; Graciela Nogueras Gonzalez; Omarya Gonzalez-Pagan; Holly A Hill; Hun Ju Lee; Luis Fayad; Jason Westin; Loretta Nastoupil; Frederick Hagemeister; Wendy Chen; Onyeka Oriabure; Maria Badillo; Changying Jiang; Yao Yixin; Shaoying Li; Guilin Tang; C Cameron Yin; Keyur P Patel; Leonard Jeffrey Medeiros; Ranjit Nair; Sairah Ahmed; Swaminathan P Iyer; Selvi Thirumurthi; Richard Champlin; Guofan Xu; Pan Tinsu; David Santos; Ruiping Wang; Guangchun Han; Jianhua Zhang; Xingzhi Song; Sattva Neelapu; Jorge Romaguera; Andy Futreal; Christopher Flowers; Nathan Fowler; Linghua Wang; Michael L Wang
Journal:  Blood Adv       Date:  2020-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.